Articles tagged with Prostate Cancer
A new three-step prostate cancer screening method can detect aggressive cancers while minimizing the detection of insignificant ones. The study found that this approach reduces unnecessary diagnoses and may lead to improved mortality rates.
Researchers at the University of Eastern Finland have identified coregulator proteins as an alternative target to prevent drug resistance in prostate cancer. By inhibiting these proteins, the growth of drug-resistant cancer cells can be inhibited, and the activity of the glucocorticoid receptor can be limited.
A culturally sensitive video addresses prostate cancer screening disparities in the Black community. The video increased knowledge and reduced uncertainty about screenings among over 600 men, leading to a 93% intent to undergo PSA screening.
A study found that proteogenomic signatures in prostate cancer tissue from patients with African and European ancestries were associated with a higher risk of metastasis and/or recurrence. The study identified mutation signatures and recurrent copy number alterations that correlated with disease progression.
A biologic drug-device combination therapy has shown promising results in treating metastatic prostate cancer, with 60% of patients experiencing an objective response. The treatment, SYNC-T, uses a cold-temperature probe to kill tumor cells and release immune-stimulating neoantigens, leading to a high response rate without severe toxic...
In a preliminary report from an ongoing clinical trial, prostate cancer screenings using PSA, Kallikrein Panel, and MRI detected higher rates of cancer compared to no screening. The study found one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected in the screened group.
A randomized clinical trial found that PSA screening compared to no routine screening resulted in a small reduction in prostate cancer deaths after 15 years. The absolute reduction in deaths was modest, but the finding suggests potential benefits of PSA screening.
The CAP trial found that PSA test screening led to a small reduction in prostate cancer deaths, but also resulted in overdiagnosis of 1 in 6 cancers. The study suggests that the benefits of screening do not outweigh the potential harms.
Integrating magnetic resonance imaging (MRI) in prostate cancer screening pathways is associated with reduced unnecessary biopsies and overdiagnosis. MRI maintains clinically significant prostate cancer detection, reducing harm from overtreatment.
A simple blood test every five years is sufficient to screen low-risk men for prostate cancer, according to new research. Researchers found that only 0.13% of men with low PSA levels developed cancer after a decade.
Global prostate cancer cases are projected to double from 1.4 million in 2020 to 2.9 million by 2040, with low- and middle-income countries seeing the highest increases. The number of annual deaths is predicted to rise by 85%, mainly in LMICs due to under-diagnosis.
A global plan to combat the projected surge in prostate cancer cases worldwide by 2040 highlights the need for increased screening among high-risk populations. The report emphasizes the importance of targeted community outreach, including mobile vans, to provide earlier diagnoses and improve treatment outcomes.
Researchers from Penn Medicine will share data on the latest advances in cancer science and medicine, including novel targets in the tumor microenvironment and the influence of the microbiome on cancer therapy. The presentation is part of the American Association for Cancer Research (AACR) Annual Meeting 2024.
Researchers found that doctors can confidently skip 50% of biopsies by combining MRI-based prostate imaging reporting and data system scores with prostate-specific antigen density testing. The study suggests that this approach can decrease patient harm and healthcare costs associated with unnecessary biopsies.
A study published in International Journal of Cancer found that men with advanced degrees and higher incomes are more likely to receive comprehensive care for prostate cancer, including MRI scans and curative treatment. This leads to lower mortality rates from the disease compared to those with lower education and income.
Patients from socially vulnerable areas show increased treatment adherence when treated at 340B-participating hospitals compared to non-participating hospitals. The study found no difference in use between 340B and non-340B hospitals but noted improved adherence among patients from disadvantaged areas.
A new study found that the COVID-19 pandemic could have led to 20,000 prostate cancer diagnoses being missed in England. The study used data from OpenSAFELY and found a significant drop in diagnosis rates during the pandemic, with a decline of 31% in 2020 and 18% in 2021.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
Researchers developed a machine-learning model to assess prostate cancer biopsy samples, overcoming limitations of traditional methods. The new model, nnU-Net, provides accurate 3D segmentation of glandular tissue structures, leading to better prognostic analyses and potential improvements in patient outcomes.
New research reveals that radioguided surgery can effectively detect and remove metastatic pelvic lymph nodes in newly diagnosed prostate cancer patients. The procedure targets the prostate-specific membrane antigen, improving nodal staging to guide treatment recommendations.
A new study found that a widely used prostate cancer test may leave black men at increased risk of overdiagnosis due to naturally higher PSA levels. The study analyzed patient records of 730,000 men and found that black men were more likely to receive a diagnosis of prostate cancer after a raised PSA test result.
A Cancer Research UK-funded study uses AI to identify two distinct subtypes of prostate cancer, termed evotypes, which could lead to personalized treatments. The discovery has the potential to improve diagnosis and treatment outcomes, saving thousands of lives in the future.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A study of over 3,500 men with prostate cancer found that a plant-based diet significantly improved measures of sexual function, urinary health, and vitality scores. The research suggests that adding more fruits and vegetables to the diet while reducing meat and dairy can have a positive impact on quality of life.
Researchers from Florida Atlantic University found that alpha-santalol, a compound in sandalwood oil, decreases cell proliferation and induces apoptosis to prevent prostate cancer development. The study showed a 53% increase in normal tissue area in treated mice, indicating protection against prostate cancer progression.
A study published in The Journal of Urology reports that racial representation matters to Black patients seeking prostate cancer information online. This lack of representation can lead to mistrust and discourage screening among Black men, who have higher rates of prostate cancer compared to White or Hispanic men.
A study reveals that Rucaparib and its metabolite M324 have differentiated activities, with M324 reducing α-synuclein accumulation in neurons from Parkinson's patients. This synergy could lead to new opportunities for treating prostate cancer and potentially developing treatments for Parkinson's.
Researchers at Northwestern University found a significant decrease in screenings for prostate cancer and urinary tract infections after implementing point-of-care alerts. The study showed a 9% reduction in PSA screenings and a 5.5% reduction in urine testing, with minimal changes in overtreatment of blood sugar.
A team of researchers from Wayne State University received a $1.4 million grant to investigate the role of cytochrome c in prostate cancer aggressiveness and the Warburg effect. The study aims to establish novel therapeutic targets to overcome treatment resistance.
Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.
Researchers discovered that depletion of the protein DPYSL5 can restore drug-responsive neuroendocrine prostate cancer cells, promoting cell transformation and lineage plasticity. This finding could lead to the development of new cancer drugs.
Research found a strong association between annual improvements in cardiorespiratory fitness and reduced risk of developing prostate cancer. Men with higher levels of fitness were 35% less likely to develop the disease than those with declining fitness. The study suggests encouraging physical activity may help lower prostate cancer risk.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
Researchers at São Paulo State University found a link between a protein-poor diet during pregnancy and an increased risk of prostate cancer in offspring. The study detected changes in the expression of over 700 genes in offspring, including the gene ABCG1, which is associated with prostate cancer.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
A new study by Northwestern University found that lab-trained AI models are easily misled by tissue contaminants, resulting in errors in diagnoses and vessel damage detection. The researchers suggest improving the problem of quantifying and addressing biological impurities in AI models to enhance accuracy.
A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment found that adverse effects of treatments on sexual function may be deemphasized in decision making for some men. The study suggests that active surveillance can be a beneficial option for patients with favorable-prognosis prostate cancer.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.
A new study found that Black patients were more likely to choose active surveillance, while those with a strong desire for a cure or expecting longer life with treatment were less likely. Education and urologist interventions can increase active surveillance adoption among low-risk prostate cancer patients.
This study explores the perspectives of primary care physicians (PCPs) and urologists on active surveillance (AS) care for men with low-risk prostate cancer. Key findings include the importance of patient education and clear communication among care team members to prevent loss to follow-up.
Researchers developed computational algorithms to analyze patient data and discovered a protein, NME2, that works closely with MYC in advanced prostate cancer cells resistant to enzalutamide. Reducing NME2 levels restored the drug's efficacy, offering new hope for patients who initially respond poorly.
A study found rectal examinations offer no advantages over PSA blood tests for detecting prostate cancer. The research analyzed data from 85,738 participants and concluded digital rectal examination alone or with PSA is not more effective than the PSA test.
Researchers developed a blood test, NEMO, to detect neuroendocrine prostate cancer (NEPC) and differentiate it from CRPC-adenocarcinoma. The test uses cell-free DNA methylation changes to quantify tumor burden and identify subtypes.
A study in the JAMA Network Open found that Hispanic and American Indian individuals with breast, colorectal, lung, and prostate cancer were undercaptured in the National Cancer Database, but representation improved over time. Further investigation is needed to understand where these populations seek cancer care.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
Researchers at UCLA Health have received a $3 million grant to identify novel biomarkers and develop AI for detecting aggressive prostate cancer. The project aims to improve treatment accuracy and reduce unnecessary interventions.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers have discovered a new approach to targeting transcription factors in prostate cancer by exploiting the formation of protein droplets. This process can be used to inhibit androgen receptor activity, which is essential for the growth and survival of cancer cells.
Two studies led by UCLA researchers reveal how cancer cells use energy to survive and grow, shedding light on why some prostate cancers become resistant to hormone therapy. The findings highlight the importance of considering cell metabolism in developing new cancer treatments, particularly those targeting the androgen receptor.
A new study found Black men diagnosed with advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy compared to white or Latino men. The disparity persisted at five years and beyond, with Black patients receiving this crucial treatment at a lower rate.
Researchers identified a correlation between the HSD3B1 biomarker and resistance to combined hormone therapy and radiotherapy in men with prostate cancer. The study found that high levels of the enzyme led to increased testosterone production, promoting resistance to treatment.
A new treatment strategy shows promise in preclinical models of advanced prostate cancer with RB1 gene loss or neuroendocrine features. Decitabine and B7-H3 targeted therapy have been shown to slow tumor growth and improve efficacy when combined.
Researchers found that monotherapy with PARP inhibitor olaparib improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer who have BRCA gene mutations. Improved responses were observed in hereditary BRCA mutations as well as spontaneous alterations.
Researchers at UNC School of Medicine have pieced together the lesser-known DNA repair pathway, polymerase theta-mediated end joining (TMEJ), which is upregulated in patients with hereditary breast cancer, ovarian cancer, and prostate cancer. The discovery could lead to new therapies for cancer by targeting this pathway.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
The PhRMA Foundation awarded two $500,000 Frontier Awards to researchers William Padula and Surachat Ngorsuraches for their patient-centered value assessment models. Their studies will advance the field of value assessment by applying theoretical models in a real-world context and engaging with patients to ensure their voices are inclu...
Researchers have identified 451 genetic variants associated with prostate cancer risk through a comprehensive analysis of nearly 950,000 men. The findings improve the accuracy of genetic risk scores and may lead to personalized screening recommendations for men at higher risk.
Researchers found that metformin restores mitochondrial activity and prevents cancer progression in mice and human prostate cells, particularly those with low NKX3.1 levels. The study suggests metformin could be used to prevent further progression of cancer in patients under active surveillance with low-NKX3.1 tumors.